PreprintAll rights reservedbioRxiv
An Injectable Antisense Oligonucleotide (ASO) Approach to Treat Obesity in Preclinical Models
- 1Baker Heart & Diabetes Institute
Related
- Gene-Specific Antisense Oligonucleotide Therapy Targeting AMA1: A Potential Malaria Treatment.
- Population-scale genome-wide prioritization of targets for allele-specific antisense oligonucleotide therapy design
- Mapping intronic mutational hotspots by in silico mutagenesis enables single antisense oligonucleotide correction of multiple variants
- Pre-Obesity and Preclinical Obesity: Disease-Specific Concepts or Generalisable Frameworks for Chronic Disease Classification?
- From cryptic exons to neuronal dysfunction: combinatorial antisense makes sense in TAR DNA-binding protein-43 (TDP-43) pathology.
BibTeX
@misc{drew2026injectable,
title = {{An Injectable Antisense Oligonucleotide (ASO) Approach to Treat Obesity in Preclinical Models}},
author = {B. G. Drew and S. T. Bond and M. F. Keating and Y. Liu and C. Yang and K. Liu and A. C. Parslow and M. Inouye and A. C. Calkin},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.12.753973},
url = {https://www.biorxiv.org/content/10.64898/2026.10.12.753973v1},
}
RIS
TY - UNPB
TI - An Injectable Antisense Oligonucleotide (ASO) Approach to Treat Obesity in Preclinical Models
AU - B. G. Drew
AU - S. T. Bond
AU - M. F. Keating
AU - Y. Liu
AU - C. Yang
AU - K. Liu
AU - A. C. Parslow
AU - M. Inouye
AU - A. C. Calkin
PY - 2026
DA - 2026/10/12
PB - bioRxiv
DO - 10.64898/2026.10.12.753973
UR - https://www.biorxiv.org/content/10.64898/2026.10.12.753973v1
ER -